DocumentsDate added
Original article:
Badyal Ashima1,*, Pandey Rajesh2, Sodhi KS2, Singh Jasbir4.
Affiliation:-
1Registrar, Department of Biochemistry, GMC, Jammu, J&K, India
2Professor,3Professor and Head, Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
The name of the department(s) and institution(s) to which the work should be attributed:
1. Department of Biochemistry, GMC, Jammu, J&K, India
2. Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
*To whom it corresponds:-
Dr. Ashima Badyal.
214-A Shastri Nagar, Jammu, J&K State, India- 180004
Contact no: +91-9796825414+91-9796825414 .
Abstract:
Context: Controversial reports are available regarding the status of magnesium on glycemic control in type 2 diabetes mellitus. Serum magnesium levels are not investigated in routine practice despite its significance. Aims: The present study was designed to compare the serum magnesium of type 2 diabetic patients without complications with those of non diabetic controls and to assess the relationship between these two. Setting and Design: Prospective cross sectional study in rural setting of Haryana. Materials and Methods: 50 healthy controls and 100 patients with type 2 diabetes mellitus without complications were recruited from Medicine OPD of MMIMSR, Mullana, Ambala (Haryana), and their serum glucose and serum magnesium levels were measured and compared. Statistical Analysis: By SPSS version 12 [SPSS v12 (SPSS Inc., Chicago, IL)]. Results: The serum magnesium levels were significantly lower in diabetic subjects. Conclusions: Serum magnesium status needs to be routinely checked in diabetic patients and, if reduced, need to be appropriately corrected.
Keywords: Complications; diabetes mellitus; glucose; magnesium.
REFERENCES
1.Parizadeh SM, Faal G, Valaee L. Maternal serum magnesium level and low birth Weight neonate. Int J Prev Med 2013; 4(12): 1476–79.
2.Zimet P, Albert KG, Shaw J. Global and societal implications of diabetes epidemic. Nature 2001; 414: 782-87.
3.Nair P, Christensen MS, Christensen C, Masbad S, Transbol I. Renal hypomagnesemia in human diabetes mellitus: its relation to glucose homeostasis. Eur J Clin Invest 1982; 12; 81-5.
4.Geiger H, Wanner C. Magnesium in disease. Clin Kidney J 2012; 5(1) 26-38.
5.Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366–73.
6.Dayanand CD, Krishamurthy N, Kiran S, Naveen. Evaluation of biochemical parameters evincing atherogenic potency in type 2 diabetic retinopathy. Int J Biol Med Res 2011; 2 (2):539-42.
7.Hans CP, Sialy R, Bansal DD. Magnesium deficiency and diabetes mellitus. Curr Sci 2002;83(12): 1456-63.
8.Paolisso G, Barbagallo M. Hypertension, diabetes mellitus and insulin resistance. The role of intracellular magnesium. Am J Hypertens 1997; 10 (3): 346-55.
9.Powers CA. Diabetes mellitus. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo BL,Jameson JL, editors. Harrison’s principles of internal medicine, 17th edition. United States of America (New York): Mc Graw Hill Company, Inc; 2008, p. 2275-2304.
10.Basak A. Development of a rapid and inexpensive plasma glucose estimation by two point kinetics method based on glucose–oxidase-peroxidase enzymes. Indian J Clin Biochem 2007; 22(1): 156-60.
11.Barbour HM, Davidson W. Studies on measurement of plasma magnesium: application of magnon dye method to the “monarch” centrifugal analyzer. Clin Chem 1988; 34: 2103-5.
12.Cockram C, Chan J. The epidemiology of diabetes in the Western Pacific Region (excluding Japan). In: Turle J, Kaneko T, Osato S, Eds. Diabetes in the New Millennium. Sydney, Pot Still Press, 1999, p. 11–22.
13.Wilson WF, Anderson M, Kannel B. Epidemiology of diabetes mellitus in the elderly the Framingham study. Am J Med 1986; 80(5): 3-9.
14.Nakagami T, Qiao Q, Tuomilehto J, Ballau B, Cartensen B, Tajima N, et al. The fasting plasma glucose cut-point predicting a diabetic 2hr OGTT glucose level depends on the phenotype.Diabetes Res Clin Pract 2002; 55: 35-43.
15.Mane M, Chaudhary RG, Reddy PE. Hypomagnesemia in diabetic patient and biochemical action on cardiovascular system. Int J Biol Med Res 2012; 3(1): 1273-76.
16.Earle C, Heshka S, Gallagher D, Wang J, Sunyer X, Richard N. Serum magnesium and type 2 diabetes in African Americans and Hispanics: a new cohort study. Am J Clin Nutr 2006;25(6): 509-13.
17.Mooren FC, Kruger K, Volker F, Golf SW, Wadepuhi M, Kraus A. Oral magnesium supplementation reduces insulin resistance in non diabetic subjects- a double blind, placebocontrolled, randomized trial. Diabetes Obes Metab 2011; 13(3):281-4.
Article citation:
Badyal Ashima,Pandey Rajesh,Sodhi KS,Singh Jasbir. Decreased Serum Magnesium in Patients with Uncomplicated Type 2 Diabetes Mellitus. J Pharm Biomed Sci. 2014;04(04):361-364.Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Original article
Niraj K Biswas1,*,Parimal H Patel2,Suresh Narayan Sharma3,Shankar Prakash4
Affiliation:-
1Assocaite professor,2Assistant Professor, Microbiology, GMERS Medical college, Valsad, Gujarat, India
3Professor,4Professor and HOD, Microbiology, PMCH, Patna, Bihar India
The name of the department(s) and institution(s) to which the work should be attributed:
1.GMERS Medical college, Valsad, Gujarat, India
2.PMCH, Patna, Bihar India
*To whom it corresponds:-
Dr Niraj K Biswas
Department of Microbiology, GMERS Medical college, Valsad, Gujarat, India
Contact no:+91-8758607152
Abstract:
Diarrhoeal diseases are a global public health problem causing considerable morbidity and mortality among infants and children especially in the developing countries. From the bacterial pathogen E.coli is constantly associated with it worldwide. Aim of the study to know prevalence of bacterial pathogen in diarrhoea in patients up to three year of age.
Materials and Methods: In duration of six month (Jan–June 2004) stool samples were collected from patients (up to 3 years of age) of diarrhoea and proceed by standard conventional method. Serological identification of isolated strains of E.Coli done at Central Research Institute Kasauli.
Results: stool samples of 125 patients were collected , in which male were more affected. E.coli isolated in 70.4% cases followed by Klebsiella sp., proteus sp., pseudomonas sp., shigella sp. and staphylococcus sp.. Isolated E.coli were of different serotype.
Conclusion: E. coli was predominant organism isolated. Serotype 055:B5 is commonest followed by 0127:B8 serotype in diarrhoea caused by E.coli.
Keywords: Diarrhoea, E.coli, serotype.
REFERENCES
1.Kamath KR. Fieldman RA. Sunder Rao, P SS & Webb, J.K.G. Infection and disease in group of south Indian families II General morbidity pattern in families and family member. Am.j of Epidemiology 89:375-383,1969.
2.Jadhav M. Report of work done on an investigation of diarhoea in infants and children ant CMC Vellore, ICMR 1965, New Delhi.
3.Kale VV, Lakshmi Iyer, & Jain MK. Shigellosis in infants and children J. Post.Grad. Med. Oct 1982; 28(4): 206-209,
4.Paveri KM. Infantile diarrhoea. Ind.J. Child health. 1952;1:418.
5.Sood S. Ind.J. Child health, 12:727,1963.
6.Sharma, S.K. Talija , R.K. Manjrekar, P.S. and Kant K.W. Ind. Paed. 1967;5:154-160.
7.Bhat PP & Mayers RM. Ind.J.Micro 1961;1:17.
8.Naruka,B.S Sharma,U. saxena,S.Aggarwal,S.S.& Sharma,M.L. Ind J.Path & Bact.Vol.13,No-6,451-455,1976.
9.Ordway NK. But Org. Mond. Sante, Bull. WHO 23: 73-101,1960.
10.Pande,R.C ,Rajvanshi, V.S and Malhotra,TN. Ind J. Path & Bact. Jan 1973;16:31.
11.Naidu,L: Study of infantile diarrhoea. Ind.J.Med.Res. 1962;50:613.
12.Tazir MA, Shrivastava KK, Khannisa SK, Aggrawal RC, Clinico-Bacteriological study of acute Gastroenteritis. Ind.J of Patho & Micro. Dec1978;85.
13.Behera SK, Mahapatra. Bacteriological study of diarrhoea in infants & childhood Ind.Paed. 1979;16:5.
14.Nath P,Bajpai PC. Amanullah, Khan AM. Ind.J.Path and Bact.1973; 16:37-41.
15.Shrivastava JR, Verma B,Garg BK. Acute diarrhoea in childhood. A clinical and bacteriological study. Ind.J.of Paed. 1968;35:217.
16.Basu B, Bhattacharya SR. Enterotoxigenicity and serotyping of E.Coli isolated from infantile gastroenteritis pt in Pune. Ind.J. Med. Res. 1983;Dec 78: 19-21.
17.Joseph Theresa. Bacteriology of diarrhoea in infants and children.Ind.J. of Micro. July-Sep.1980;20:3.
18.Sen Gupta SR,Sharma KD. Ind .J. Path and Bact. 1967;10:304.
19.Pande RC. Bacteriology of infantile diarrhoea and Gastroenteritis in Allahabad. Ind.J.Path & Micro. 1976;19:169.
20.Manorma Dev, Bhagwala R.A, Shriniwas & Singh,Maherbhan.Klebsiella pneumonia as the possible cause of an outbreak of diarrhoea in a neonatal special care unit. Ind.J.Med. March 1980;Res.71:359-362.
21.Arora MM, Pohowalla JN. Diarrhoea in infancy and childhood, Ind.J.Child Health. 1955;4:559.
22.Romas Alvarez M and Olate J, Diarrhoeal disease of children. The occurrence of enteropathogenic viruses and bacteria.Amer.J.Dis.child 1964;107:218.
23.Dmitrieva N, Zakaryan L.M. Staphylococcus in intestinal infection in infants.Abstracted in Excepta Medica (Paed), 1964;18:777.
24.Manchanda SS, Arora NN. Acute gastroenteritis in infants and young children with special reference to some etiological factors. Ind.J.Paed.1958;25:539.
25.Ahmed R, Bopp C. Phage typing scheme for Esch. Coli 0157:H7. J.Infect.Dis. 1987;155:806-809.
Article citation:
Biswas NK,Patel PH,Sharma NS,Prakash S. Study of prevalence of Bacterial pathogen as causative agent of diarrhoea in 0-3 years patients attending a Tertiary care Hospital Patna, Bihar,India. J Pharm Biomed Sci 2014; 04(03): 371-374. Available at www.jpbms.info.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Original article
Panigrahi R1,* Maheshwari A2
Affiliation:-
1Associate professor, 2P.G Student,Department of Otorhinolaryngology, Hi-Tech Medical college and Hospital, Bhubaneswar, Odisha, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Otorhinolaryngology, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
*To whom it corresponds:-
Dr. Rajlaxmi Panigrahi, M.S.
Associate professor,
Department of Otorhinolaryngology, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Contact no:- +91- 09437113636+91- 09437113636
Abstract
Background: Oral submucosal fibrosis (OSMF) is a chronic, crippling condition of oral cavity with a well recognized malignant potential. Its multifactorial etiology and treatment regimes are yet to be standardized. In the present study, the efficacy of combination of triamcinolone acetonide and hyaluronidase has been compared with triamcinolone acetonide alone, given intralesionally at 14 days interval.
Material and method: In a prospective study, patients of OSMF were randomly divided into 2 groups (A and B). Patients in group A received a combination of triamcinolone acetonide and hyaluronidase. Patients in group B received triamcinolone acetonide (1500 IU) alone. In both groups, medication was injected submucosally at 14 days interval, for a total of 8 doses. Treatment outcome was evaluated in terms of improvement in mouth opening and symptom score. Students paired ‘t’ test was used for result comparison.
Result: Patients in group A showed a statistically significant improvement than those in group B. with no complications in either group.
Conclusion: Intralesional injection of combination of triamcinolone acetonide and hyaluronidase is superior to triamcinolone alone, in respect to improvement in symptoms and patient convenience. A follow up study is needed to assess the long term effects.
Keywords: Oral Submucosal Fibrosis [OSMF]; Triamcinolone Acetonide [TA]; Hyaluronidase [HY].
REFERENCES
1.Pindborg JJ, Barmes D, Roed-Peterson B. Epidemiology and histology of oral leukoplakia and leukoedema among Papuans and New Guineans. Cancer 1968;22:379-84.
2.Mukherji AL, Biswas SK. Oral submucous fibrosis – A search for etiology. Indian J Otolaryngol. 1972;24:11-5.
3.Desa JV. Submucous fibrosis of the palate and cheek. Ann OtolRhin and Laryng 1957;66:1043-59.
4.Pindborg JJ. Oral submucousfibrosis : A review. Ann Acad Med Surg1989;18:603-7.
5.Anuradha CD, Devi CS. Serum protein, ascorbic acid and iron and tissue collagen in oral submucous fibrosis– a preliminary study. Indian J Med Res 1993;98:147-51.
6.Ariyawardhana A, Athukorala AD, Arulanandam A. Effect of betel chewing, tobacco smoking and alcohol consumption on oral submucous fibrosis: A case-control study in Sri Lanka. J Oral Pathol Med 2006;35(4):197-201.
7.Ahmed MS, Ali AS, Ali SA, et al. Epidemiological and etiological study of oral submucous fibrosis among gutkha chewers of Patna, Bihar, India. J Indian SocPedodprev Dent 2006:24(2):84.
8.ElluruVenkatesh et al: Role of Corticosteroids in Dentistry. Archives of dental sciences review article. 2010;1(1):3-11.
9.Anil GG. Text book of oral medicine.Jaypeebrothers medical publishers (P) ltd 2010.
10.Kakar PK, Puri RK, Venkatachalam VP.Oral suubmucous fibrosis–Treatment with hyalase. J LaryngolOtol 1985;99:57-59.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Article citation:
Panigrahi R, Maheshwari A. A prospective, randomized double blind study comparing intralesional triamcinolone acetonide and hyaluronidase combination versus triamcinolone acetonide alone in the treatment of oral submucosal fibrosis. J Pharm Biomed Sci 2014;04(04):365-370. Available at www.jpbms.info.
Copyright © 2014 Panigrahi R, Maheshwari A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:
Trivedi Grishma1,*, Nerurkar Alka B2
Affiliation:-
1Assistant Professor, 2Professor & Head, Microbiology Department, GMERS Medical College & Hospital, Valsad, Gujarat, India.
The name of the department(s) and institution(s) to which the work should be attributed:
Microbiology Department, GMERS Medical College& Hospital, Valsad, Gujarat, India
*To whom it corresponds:-
Dr. Grishma Trivedi.
Assistant Professor, Department of Microbiology, GMERS Medical College & Hospital, Valsad, Gujarat, India.
Email: drgrtrivedi@gmail.com
Abstract:
Introduction: HIV infection is a global epidemic. In India, HIV was first detected in commercial sex workers in Tamil Nadu in 1986 and since then, the infection is growing quite fast with geographic variation. The epidemiology of HIV in rural India is not well known and rural residents have been underrepresented, despite 67% of HIV infected people live in rural areas.
Aim: To find out the sero-prevalence of HIV infection in a rural tertiary care teaching hospital.
Material & Method: A retrospective analysis was carried out, of 3802 participants enrolled at Integrated Counseling and Testing Center (ICTC) attached to our tertiary care teaching hospital. HIV sero-positive participants were further analysed on the basis of age, sex and possible routes of transmission.
Results: Out of 3802, 1909 (50.21%) were males, 1887 (49.63%) were females and 06 (0.16%) were Trans-sexual/Transgender (TS/TG). Amongst the total of 3802 participants, 175 (4.6%) were proved to be positive for HIV-1 infection. Prevalence of HIV infection among males was 104 (5.45%), females was 67 (3.55%) and TS/TG was 4 (66.7%); while the most common transmission route was heterosexual (n=158, 90.3%), followed by vertical (n=15, 8.6%) and homosexual/Bisexual (n=2, 1.14 %).
Conclusion: More studies are required for population residing in rural areas as HIV epidemic appears to be moving from urban to rural populations..
Keywords: HIV; Rural tertiary care hospital; Sero-prevalence; Trans-sexual/Transgender population.
REFERENCES
1.Fauci AS, Lane HC. Human immunodeficiency virus disease: AIDS and related disorders. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison's Principles of Internal Medicine, 18th ed. USA: The McGraw-Hill companies, Inc., 2012; pg:1506-1587.
2.AIDS epidemic, 2006: AIDS epidemic update 2007. (Online) Cited 2009 April). Available from URL:http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdfg.
3.Godbole S, Mehendale S. HIV/AIDS epidemic in India: risk factors, risk behavior & Strategies for prevention & control. Ind J Med Res 121, April 2005, pp 356-368.
4.National AIDS Control Organization. Ministry of Health & Family Welfare, Government of India. HIV Sentinel Surveillance 2006 India Country Report. Available from: http://www.nacoonline.org/Quick_Links/Publication/ME_and_Research_Surveillance/Reports_and_Surveys/HIV_Sentinel_Surveillance_2006_India_Country_Report/
5.NACO (2007) Guidelines on HIV Testing. National AIDS Control Organisation Available: http://www.nacoonline.org/upload/Final%20Publications/Blood%20Safety/GUILDELINES%20FOR%20HIV%20TESTING.pdf. Accessed 12 December 2013.
6.Mir MA et al. Clinical and demographic profile of HIV/AIDS patients diagnosed at a tertiary care center in Kashmir. J Pak Med Assoc June 2010; Vol. 60, pg:428-431.
7.Gerardo Alvarez-Uria et al. Gender differences, routes of transmission, socio-demopgraphic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infectious Disease Reports 2012; Volume 4:e19, pg 66-70.
8.Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-9.
9.May M, Gomples M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011;343.
10.Vyas KJ et al. A comparison in HIV-associated stigma among healthcare workers in urban and rural Gujarat. Journal of Social Aspects of HIV/AIDS; Vol. 7, Iss. 2 August, 2010; pg:71-75
11.Abdul Karim Q, Abdool Karim SS, Singh B, Short R, Ngxongo S. Sero-prevalence of HIV infection in rural South Africa. AIDS; 1992 Dec; 6(12):1535-9.
12.Sekar et al. Recent trends in HIV prevalence in a remote setting of southern India: Insights into arranging HIV control policies.
13.Asia Pacific Coalition on Male Sexual Health (APOCOM), Mapping Transgender Groups, Organisation & Networks in South Asia, 2008; Available at http://www.msmasia.org.
14.WHO, Prevention and Treatment of HIV & Other Sexually Transmitted Infections Among Men Who Have Sex With Men & Transgender People:Recommendations for a Public Health Approach, June 2011; Available at http://www.who.int/hiv/pub/guidelines/msmguidelines2011/en/index.html, P.10.
15.HIV & Transgendered/Transexual Communities; Integragency Coalition on AIDS & Development, August 2011; Available at http://icad-cisd.com.
16.UNAIDS/WHO. Country Progress Report. UNGASS. India, March 2010. Available from: http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountries/india_2010_country_progess_report_en.pdf
17.Vlassoff C, Weiss MG, Rao S, Ali F, Prentice T. HIV-related stigma in rural and tribal communities of Maharashtra, India.
Article citation:
Trivedi Grishma, Nerurkar AB. Seroprevalence of HIV infection in a rural tertiary care teaching hospital of South Gujarat from January To December 2012. J Pharm Biomed Sci 2014;04(04):356-360.Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Trivedi Grishma, Nerurkar AB. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article:
N. Lakshmidevi1,*, Khadega Yahyah A. Al-hetar1, G B Kavishankar1,2
Affiliation:-
1Department of Studies in Microbiology, University of Mysore, India
2Department of Studies in Biochemistry, University of Mysore, India
The name of the department(s) and institution(s) to which the work should be attributed:
University of Mysore, India
*To whom it corresponds:-
N. Lakshmidevi
Department of Studies in Microbiology, University of Mysore, India
Ph: +91-0821-2419739+91-0821-2419739
Abstract
Escherichia coli is a commensal bacterium but it can cause different infections for humans and animals after acquisition of virulence factor genes and with the time and by the random usage of antibiotics. It gains resistant to antibiotics that can be transmitted by E. coli to other pathogenic bacteria. Many measures and investigations should to be taken as a kind of prevention and to reduce the damages that will be caused by E. coli.
Keywords: E. coli, ESBLs, Phylogenetic Groups, Resistance Genes, Virulence Factors.
Article citation:
Lakshmidevi N, Al-hetar KY,Kavishankar GB. Extended Spectrum Beta Lactamase Producing Extraintestinal Pathogenic Escherichia coli (ESBL-ExPEC). J Pharm Biomed Sci 2014;04(04):343-355. Available at www.jpbms.info.
REFERENCES
1.Al-Jasser AM. Extended-Spectrum Beta-Lactamases (ESBLs): A Global Problem. J Kuwait Med Assoc 38. 2006;3:171-185.
2.Alobwede I, M'Zali FH, Livermore DM, Heritage J, Todd N, Hawkey P M,. CTX-M extended-spectrum β-lactamase arrives in the UK. J. Antimic.l Chemo. 2003;51: 470-471.
3.Arisoy M, Rad AY, Akan A, Akar N. Relationship between susceptibility to antimicrobials and virulence factors in pediatric Escherichia coli isolates. Int J Antimic Agen. 2008;31: 4-8.
4.Atifah MN, Loo H, Subramaniam G, Wong E, Selvi P, Ho S, Kamarulzaman A, Parasakthi N,. Faecal prevalence of extended-spectrum β-lactamase (ESBL)-producing coliforms in a geriatric population and among haematology patients. Malays J Pathol. 2005;27(2):75-81.
5.Baldy-Chudzik K, Mackiewicz P, Stosik M. Phylogenetic background, virulence gene profiles, and genomic diversity in commensal Escherichia coli isolated from ten mammal species living in one zoo. Vetmic.2008;3977.
6.Bekal S, Brousseau R, Masson K, Prefontaine G, Fairbrother J, Harel J,. Rapid Identification of Escherichia coli Pathotypes by Virulence Gene Detection with DNA Microarrays. J Clin Micro. 2003;41(5):2113–2125.
7.Blanco1 M, Alonso M, Nicolas-Chanoine M, Dahbi G, Mora A, Blanco, J, Lo´pez1 C, Corte´s P, Llagostera, M. Molecular epidemiology of Escherichia coli producing extended-spectrum b-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J Anti Chemo. 2009;63:1135–1141.
8.Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Anti Agen &Chemo.2004;48(1):1-14.
9.Bradford PA, Yang Y, Sahm D, Grope I, Gardovska D, Storch G. CTX-M-5, a novel cefotaxime-hydrolyzing β-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimic. Agen. & Chemo. 1998;42(8):1980-1984.
10.Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, Gouriou S, Piacard B, Denamur E. Genetic background of Escherichia coli and extended-spectrum β- lactamase type. Eme Infec Dise. 2005;11(1):54-61.
11.Carlos C, Pires M, Stoppe N, Hachich E, Sato M, Gomes T, Amaral L, Ottoboni L. Escherichia coli phylogenetic group determination and its application in the identification of the major animal source of fecal contamination. Bio Cent Micro. 2010; 10:161.
12.Chapman TA, Wu X, Barchia I, Bettelheim K, Driesen S, Trott D, Wilson M, Chin J. Comparison of virulence gene profiles of Escherichia coli strains isolated from healthy and diarrheic swine. Appli & Envir Micro.2006;72 (7):4782–4795.
13.Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, Venezia SN. CTX-M-2 and a new CTX-M-39 enzyme are the major extended in spectrum beta-lactamases multiple Escherichia coli clones isolated in Tel Aviv, Israel. Anti Agen &Chemo. 2005;49 (11): 4745-4750. 14. Chroma M, Kolar M. Genetic Methods For Detection of Antibiotic Resistance: Focus on Extended-Spectrum β-Lactamases. Biomed Pap. Med. Fac. Univ. Palaky Olomouc Czech Repup. 2010, 145(4):289-296.
15.Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic groups. Appli & Envir Micro. 2000; 66 (10):4555-4558.
16.Clermont O, Johnson J, Menard M, Denamur E. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diag Micr & Infec Dis.2007;57:129–136.
17.Dutour C, Bonnet R, Marchandin H, Boyer M, Chanal C, Sirot D, Sirot J,. CTX-M-1, CTX-M-3, and CTX-M-14 β- lactamases from Enterobacteriaceae isolated in France. Antimic Agen & Chemo. 2001;46 (2):534-537.
18.Eckeret C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, Barnaud G, Delisle F, Rossier A, Lambert T, Philippon A, Alert G,. Dissemination of CTX-M-type β-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Anti Agen & Chemo. 2004; 48(4):1249-1255.
19.Eisner A, Fagan E J, Feierl G, Kessler H H, Marth E, Livermore DM, Woodford N. Emergence of enterobacteriaceae isolated producing CTX-M extended-spectrum β-lactamase in Austria. Antimi. Agen. Chemo. 2006;50(2):785-787.
20.Emody L, Pál T, Hacker J, Blum-Oehler G. Genes and proteins underlying microbial urinary tract virulence basic aspects and applications. New York. Kluw Acade Publis. 2002.
21.Escobar-Páramo P, Menac’h A, Gall T, Amorin A, Gouriou S, Picard B, Skurnik D, Denamur E. Identification of forces shaping the commensal Escherichia coli genetic structure by comparing animal and human isolates. Enviro Microb.2006; 8(11):1975–1984.
22.Gordon D, Cowling A. The distribution and genetic structure of Escherichia coli in Australian vertebrates: host and geographic effects. Microb. 2003;149:3575–3586.
23.Guibout VL, Jurand C, Bonacorsi S, Espinasse F, Guelfi MC, Duprotail F, Heym B, Bingen E, Chanoine MHN. Emergence and spread of three clonally related virulent isolated of CTX-M-15-producing Escherichia coli with variable resistance to aminoglycosdes and tetracycline in a France geriatric hospital. Anti Agen & Chemo. 2004;48(10): 3736-3742.
24.Hamelin K, Bruant G, El-Shaarawi A, Hill S, Edge TA, Fairbrother J., harel J, Maynard C, Masson L, Brousseau R. Occurrence of virulence and antimicrobial resistance genes in Escherichia coli isolates from different aquatic ecosystems within the St. Clair River and Detroit river areas. Appli & Enviro Micro. 2006;73(2):477-484.
25.Highland M, Byrne B, DebRoy C, Samitz E, Peterson T, Oslund K. Extraintestinal pathogenic Escherichia coli induced pneumonia in three kittens and fecal prevalence in a clinically healthy cohort population. J Veteri Diagno Invest.2009;21:609.
26.Ho PL, Wong RC, Chow KH, Yip K, Wong SS, Que TL. CTX-M type beta-lactamases among fecal Escherichia coli and Klebsiella pneumoniae isolates in non- hospitalized children and adults. J Micro Immun & Infect.2008;41:428-432.
27.Hoek AH A, Mevius D, Guerra B, Mullany P, Roberts AP, Aarts HJM. Acquired antibiotic resistance genes: an overview. Front. in Microb. 2011;2(203):1-27.
28.Hudault S, Spiller B, Morgan P, Servin A. Human diffusely adhering Escherichia coli expressing afa/dr adhesins that use human CD55 (Decay-Accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55. Infect & Immu. 2004;72(8): 4859–4863.
29.Hull R, Bieler S, Falkow S, Hull S. Chromosomal map position of genes encoding P adhesins in uropathogenic Escherichia coli. Infect & Immun. 1985;51(2):693-695.
30.Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, Carbonnelle, E, Lortholary, O, Clermont, O, Denamur, E, Picard, B, Nassif, X, Brisse, S. Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BioM Cent Geno. 2008;9(560):1-14.
31.Jayaraman R. Antibiotic resistance: an overview of mechanisms and a paradigm shift. Curr Sci India. 2009;96:1475–1484.
32.Jeong SH, Bae IK, Kwon SB, Lee JH, Song JS, Jung HI, Sung KH, Jang SJ, Lee SH. Dissemination of transeferable CTX-M-type extended- spectrum β-Lactamase- producing Escherichia coli in Korea. J Appli Microb.2005;98:921-927.
33.Johnson J, Russo T, Tarr P, Carlino U, B. Svary J, Stell A. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN E. coli, among Escherichia coli isolates from patients with urosepsis. Infect & Immun.2000; 68(5):3040–3047.
34.Johnson J, Delavari P, Kuskowski M, Stell A. Phylogenetic distribution of extra intestinal virulence-associated traits in Escherichia coli. J Infect Dise. 2001;183:78–88.
35.Johnson JR, Kuskowski MA, Owens K, Gajewski A, Winokur PL. Phylogenetic origin and virulence genotype in relation to resistance to flouroquinolones and/or extended-spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans. J Infec Dise.2003;188:759-768.
36.Johnson J, Jelacic S, Schoening L, Clabots C, Shaikh N, Mobley H, Tarr P. The irgA homologue adhesin iha is an Escherichia coli virulence factor in murine urinary tract tnfection. Infect & Immu.2004;73(2):965–971.
37.Johnson JR, Kuskowski MA, O’Bryan TT, Colodner R, Raz R. Virulence genotype and phylogenetic origin in relation to antibiotic resistance profile among Escherichia coli urine sample isolates from Israeli women with acute uncomplicated cystitis. Anti Agen & Chemo.2005; 49(1):26-31.
38.Johnson J, Owens K, Clabots C, Weissman S, Cannon S. Phylogenetic relationships among clonal groups of extraintestinal pathogenic Escherichia coli as assessed by multi-locus sequence analysis. Micro & Infect. 2006;8:1702-1713.
39.Johnson JR, Menard M, Johnston B, Kuskowski MA., Nichol K, Zhanel G G. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antim. Agen Chemo. 2009;53:2733–2739.
40.Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence typeST131as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 2010;51:286–294.
41.Karisik E, Ellington MJ, Livermore DM, Woodford N. Virulence factors in Escherichia coli with CTX-M-15 and other extended spectrum β-lactamases in the UK. J Anti Chemo.2007;61: 54-58.
42.Kere´nyi M, Allison H, Ba´tai I, Sonnevend A, Emo¨dy L, Plaveczky N, Pa´l1 T. Occurrence of hlyA and sheA genes in extraintestinal Escherichia coli strains. J Clin Micro. 2005;43(6):2965–2968.
43.Kiratisin P, Apisarnthanark A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumonia isolated causing health care-associated infection in Thailand, where the CTX-M family is endemic. Anti Agen & Chemo. 2008; 52(8): 2818-2824.
44.Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumonia and Serratiamarcescens. J Infec. 1983; 11: 315-317.
45.Kuntaman K, Lestari ES, Severin JA, Kershof IM, Mertaniasih NM, Purwanta, M., Hadi, U, Johnson JR, Belkum A, Verbrugh HA. Fluoroquinolone-resistant Escherichia coli, Indonesia. Emer Infect Dis. 2005;11 (9):1663-1669.
46.Lambert PA. Bacterial resistance to antibiotics: modified target sites. Adv Drug Deliv Rev.2005;57: 1471–1485.
47.Lavigne JP, Marchandin H, Delmas J, Moreau J, Bouziges N, Lecaillon E, Cavalie L, Pierre HJ, Bonnet R, Sottoo A. CTX-M β-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Micro. 2006;45(2):620-626.
48.Lavigne JP, Blanc–Potard AB, Bourg G, Moreau J, Chanal C, Bouziges N, Callaghan DO, Sotto A. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M β-lactamases. J Clin Micro & Infec Dis. 2006;12(12): 1199-1206.
49.Lecointre G, Rachdi L, Darlu P, Denamur E. Escherichia coli Molecular phylogeny using the incongruence length difference test. The Soci for Molec Bio & Evol. 1998; 15(12): 1685–1695.
50.LewisII JS, Herrera M, Wicker B, Patterson JE, Paterson JH. First report of the emergence of the CTX-M-type extended-spectrum β-lactamase (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Anti Agen & Chemo. 2007; 51(11): 4015-4021.
51.Machado E, Canton R, Baquero F, Galan JC, Rollan A, Peixe L, Coque TM. Integron content of extended-spectrum-β-lactamase-producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain. Anti Agen & Chemo. 2005; 49 (5): 1823-1829.
52.Mamlouk K, Boubaker IB, Gautier V, Vimont S, Picard B, Redjeb SB, Arlet G. Emergence and outbreak of CTX-M β-lactamase-producing Escherichia coli and Klebsiella pneumonia strains in a Tunsian hospital. J Clin Micro. 2006; 44 (11): 4049- 4056.
53.MainousIII AG, Pomeroy C. Management of antimicrobials in infectious diseases. Totowa, New Jersey: Humana Press. 2001.
54.Manges A, Tabor H, Tellis P, Vincent C, Tellier P. Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections. Emer Infec Dis. 2008; 14 (10): 1575-1583.
55.Manning SD. Deadly diseases and epidemics Escherichia coli infections. USA: Chelsea House Publishers. 2004.
56.Martinez LM, Fernnandez F, Perea EJ. Relationship between Haemolysis production and resistance to fluoroqunolones among clinical isolates of Escherichia coli. J Anti Chemo. 1999; 43: 277-279.
57.McCraken M. Characterization of extended-spectrum beta-lactamases (ESBLs) in North America. University of Manitoba, Canada, 2006.
58.Meier C, Oelschlaeger TA, Merkert H, Korhonen TK, Hacker JR. Ability of Escherichia coli isolates that cause meningitis in newborns to invade epithelial and endothelial cells. J Infec & Immun. 1996; 64 (7): 2391-2399.
59.Mendonca N, Leitoe J, Manageiro V, Ferreira E, Canica M. Spread of extended-spectrum β-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Anti. Agen & Chemo. 2007; 51(6): 1946-1955.
60.Mora A, López C, Dabhi G, Blanco M, Blanco J, Alonso M, Herrera A, Mamani R, Bonacorsi S, Moulin-Schouleur M, Blanco J. Extra intestinal pathogenic Escherichia coli O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and DST59 with different host distribution. BioM Cent Micro. 2009; 9(132).
61.Moreno JE, Planells I, Prats G, Planes AM, Moreno G, Andreu A. Comparative study of Escherichia coli virulence determinants in strains causing urinary tract bacteremia versus strains causing pyelonephritis and other sources of bacteremia. Diag Micro & Infect Dis. 2005; 53: 93-99.
62.Nazareth H, Genagon SA, Russo T. Extraintestinal pathogenic Escherichia coli survives within neutrophils. Infec & Immun. 2007; 75 (6): 2776–2785.
63.Nicolle L, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada Guidelines Committee.. Complicated urinary tract infection in adults. The Can J of Infect Dis & Med Micro. 2005; 16 (6): 349-360.
64.Nowicki B, Selvarangan R, Nowicki S. Family of Escherichia coli dr adhesins: decay-accelerating factor receptor recognition and invasiveness. J Infec Dis. 2001; 183 (1): 24-27.
65.Nowrouzian F, Adlerberth I, Wold A. Enhanced persistence in the colonic microbiota of Escherichia coli strains belonging to phylogenetic group B2: role of virulence factors and adherence to colonic cells. Micro& Infect. 2006; (8):834-840.
66.Obata-Yasuoka M, Ba-Thein W, Tsukamoto T, Yoshikawa H, Hayashi H, Vaginal Escherichia coli share common virulence factor profiles, serotypes and phylogeny with other extra intestinal E. coli. J Microb. 2002; 148: 2745–2752.
67.Oelschlaeger TA, Dobrindt U, Hacker J. Pathogenicity islans of uropathogenic E. coli and the evolution of virulence. Inter J Anti Agen. 2002; 19: 517-521.
68.Pagani L, Amico ED, Migliavacca R, D’Andrea MM, Giacobone E. Amicosante G, Romero E, Rossolini GM. Multiple CTX-M-type extended spectrum β-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in Northen Italy. J Clin Micro. 2003; 41(9): 4264-42-69.
69.Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microb Rev. 2005; 18(4): 657-686.
70.Peirrano G, vanderBij AK, Greg- son DB, Pitout JD. Molecular epidemiology over an eleven-year period (2000-10) of extended-spectrum beta-lactamase- producing Escherichia coli causing bacteraemia in a centralized Canadian region. J. Clin .Microbiol. doi. 2011; 50(2):294-299.
71.Piatti G, Mannini A, Balistreri M, Schito AM. Virulence factors in urinary Escherichia coli strains: Phylogentic background and quinolone and flouroquinolone resistance. J Clin Microb. 2007;46 (2):480-487.
72.Picard B, Garcia JS, Gouriou S, Duriez P, Brahimi N, Bengen D, Elion J, Denamur E. The link between phylogeny and virulence in Escherichia coli extra intestinal infection. J Infec & Immun. 1998;67(2): 546-553.
73.Pitout JDD, Laupland KB, Church DL, Menard ML, Johnson JR. Virulence factors of Escherichia coli isolates that produce CTX-M type extended-spectrum β-lactamases. Anti Agen & Chemo. 2005; 49(11):4667-4670.
74.Pitout JDD, Laupland KB. Extended spectrum beta-lactamases producing Enterobacteriaceae: an emerging public health concern. Lancet. Infect. Dis. 2008; 8:159-166.
75.Pitout JD, Gregson, DB, Camp-bell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to2007: emergenceofclone ST131 as a cause of community-acquired infections. Anti. Agen Chemo. 2009; 53:2846–2851.
76.Pitout JD. Extra-intestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Anti Agen & Chemo. 2012; 3(9): 1-7
77.Poirel L, Kampfer P, Nordamann P. Chromosome encoded ambler class A β-lactamases of Kluyvera Georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Anti Agen & Chemo. 2002;46(12) 4038-4040.
78.Prelog M, Fille M, Prodinger W, Grif K, Brunner A, Würzner R, Zimmerhackl LB. CTX-M-1-Related Extended-Spectrum Beta-Lactamases Producing Escherichia coli: so far a Sporadic Event in Western Austria. J. of Infect. 2008;36 (4):362-367.
79.Queener SF, Webber JA, Queener SW. Beta-lactam antibiotics for clinical use. New York. Marcel Dekker. 1986.
80.Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, Steward C, Hill B, Medeiros AA, Tenover FC. Evolution of extended spectrum β- lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Anti Agen & Chemo. 1997;41(3):646-653.
81.Rogers BA, Sidjabat HEm, Patreson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Anti. Chemo. 2011; 66:1-14.
82.Russo T, Carlino U, Mong A, Jodush S. Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine. Infect & Immun. 1999; 67(10): 5306.
83.Russo TA, Johnson JR,. Medical and economic impact of extra-intestinal Infections Due to Escherichia coli: focus on an increasingly important endemic problem. J Mic.& infect. 2003; 5: 449-456.
84.Ryan KJ, Ray CG. Sherris medical microbiology: An introduction to infectious diseases. USA. The McGraw-Hill Companies.2004.
85.Ryoo NH, Kim E, Hong SG, Park YJ, Lee K, Bae IK, Song EH, Jeong SH. Dissemination of SHV-12 and CTX- M-type extended-spectrum β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Anti Chemo. 2005;56:698-702.
86.Sabate M, Prats G, Moreno E, Balleste E, Blanch AR, Andreu A. Virulence and antimicrobial resistance profiles among Escherichia coli strains isolated from human and animal wastewater. Res Microb. 2008;159:288-293.
87.Schouleur MM, Reperant M, Laurent S, Laurent S, Bree A. Extra-intestinal pathogeneic Escherichia coli strains of avian and human origin: link between phylogenetic relationships and common virulence patterns. J Clin Microb. 2007;45(10):3366-3376.
88.Schwertmann A, Schroten H, Hacker J, Kunz C. S-fimbriae from Escherichia coli bind to soluble glycoproteins from human milk. J Ped Gastr & Nutr. 1999;28(3):257-63.
89.Servin AL. Pathogenesis of afa/dr diffusely adhering Escherichia coli. clin Microb Rev. 2005; 18 (2):264–292.
90.Sharma S, Bhat G, Shenoy S. Virulence factors and drug resistance in Escherichia coli isolated from Extra-intestinal infections. Indi J Med Microb. 2007; 25 (4):369-373.
91.Siu LK, Lu PL, Hsueh PR, Lin MF, Chang SC, Luh KT, Ho M, Lee CY,. Bacteremia due to extended- spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J Clin Microb. 1999;37(12):4020-4027.
92.Subramaian G, Palasubramanian S, Navartanam P. SHV-5 extended spectrum β-lactamases in clinical isolates of Escherichia coli in Malaysia. Indi J Med Microb. 2006;24(3):205-207.
93.Talaro KP, Talaro A. Foundations in microbiology: Basic principles. New York. McGraw-Hill, 2002
94.Tarr P, Bilge S, Vary J, Jelacic S, Habeeb H, Ward T, Baylor M, Besser T. Iha: a novel Escherichia coli O157:H7 adherence-conferring molecule encoded on a recently acquired chromosomal island of conserved structure. Infect Immun. 1999;68(3): 1400-1407.
95.Todar, K., 2008. Pathogenic E. coli. U.S.A. (www.textbookofbacteriology.net).
96.Tofteland E, Haldorson B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, Sundsfjord A, The Norwegian ESBL study group. Effect of phenotype and genotype on methods for detection of extended-spectrum-β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microb. 2006;45(1): 199-205.
97.Vimont S, Aubert D, Mazoit JX, Poirel L, Nordman P. Broad spectrumβ Lactams for treating experimental peritonitis in mice due to Escherichia coli Producing plasmid-encoded cephalosporinases. J Anti Chemo. 2007;60:1045-1050.
98.Wiles T, Kulesus R, Mulvey M,.Origins and virulence mechanisms of uropathogenic Escherichia coli. Exper. & Molec. Patho. 2008;85(1):9-11.
99.Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, leach JB, Loughrey A, Lowes JA, Warren RE, Livermore DM. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimic. Chemo. 2004;54:735-743.
100.Yu Y, Ji S, Chen,Y, Zhou W, Wei Z, Li L, Ma Y. Resistance of strain producing extended-spectrum β-lactamases and genotype. J Infec. 2007; 54:53-57.
101.Zhang L, Foxman B, Marrs C. Both urinary and rectal Escherichia coli isolates are dominated by strains of phylogenetic group B2. J Clin Microb, 2002; 40(11):3951–3955.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Lakshmidevi N, Al-hetar KY,Kavishankar GB. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.